about
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderA systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorderEvaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.Nicotinic acetylcholine receptors as targets for antidepressants.Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.Generalized anxiety disorder: comorbidity, comparative biology and treatment.Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.The Psychological and Medical Factors Associated With Untreated Binge Eating DisorderAtypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.An evidence-based review of the clinical use of sertraline in mood and anxiety disorders.Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder.A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.Restoring function in major depressive disorder: A systematic review.Diagnostic errors of primary care screens for depression and panic disorder.Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.Sheehan Suicidality Tracking Scale (S-STS): reliability, convergent and discriminative validity in young Italian adults.Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.Content validity of the Sheehan Irritability Scale in patients with major depressive disorder.Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder.Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.Importance of Restoring Function in Patients With Major Depressive Disorder.Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs.Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.The diagnosis and drug treatment of anxiety disorders.Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).A diagnostic aid for detecting (DSM-IV) mental disorders in primary care.
P50
Q24564427-D0988323-5980-4C82-9019-87573F91D177Q28072401-6E127126-E2B3-4E58-895C-0E98EBA0D336Q30562259-5876CA74-F1D4-45E1-81F4-0876FD54B21CQ30679519-A5E1B332-A35C-4521-AE43-0625157A0CA4Q34761238-8697E2B6-E3C5-4127-BDF0-0340A2F7D1A7Q34844050-A45028EC-B58C-478B-99B7-691BE5A1A90DQ35016988-386B364C-B4F4-469A-A1B7-9A3D4508DF5DQ36007894-090B5825-7C30-4745-A312-E1174EA809B3Q36028291-C8CA51BD-2135-425F-88DE-75F5AF0AF789Q36205791-1EE614DD-836A-47CC-B1D9-7A91422F3AD1Q37308842-DB379536-46E3-4D16-AFF8-2A321768361EQ37694366-88B6864D-615C-444A-9CB0-6E7D4775C657Q37776770-86CEF3E7-9977-4352-B7EA-1C224C3F256EQ37783373-32224414-0117-4ADF-A28E-D6703532B009Q37860262-4FC0CB06-3163-453B-B860-82DF44F14429Q38392059-E4ADABF7-093D-4C1B-96EF-09898D87DC48Q38399891-86236A79-5628-482A-AF8A-EF092B7D689BQ38439259-CFE9FDDA-9BBF-4AAC-BACB-258B165F19BBQ39212540-0224F366-9510-45D5-B6E7-CBAFFA1FB951Q41673824-C2B6664A-D4F0-42B6-9A92-8CAA168F1D90Q43418227-D69AC13C-C020-4CE3-A18A-ACF5F100C626Q43860455-B54D1AB8-EFD4-4704-A418-51BD3B16A059Q44385588-C2148713-61C7-4B4F-BBC3-7CF476893D33Q45003561-B560DE92-6C3D-4FA6-8502-1982EB98BFA1Q45023370-EA8D3EF2-2F31-401B-B202-47D5964188D1Q45045046-3E1829AC-0B13-48EF-9507-B949C206DBB9Q45418936-F9AF5348-8731-4B4A-AE11-19E223BE9333Q46013635-D5676F9E-24BE-4E65-8248-5C2FAC7ADB77Q46223112-15F6BDF9-F8F6-4395-8D60-B27407093146Q46327840-A86D4949-70F8-403B-979C-3A5FE3C29EF3Q47765264-97255773-9506-4012-8F53-FF066F406B98Q48047225-B947C6F2-8D04-4820-9F1E-BD4242406E3BQ48229801-147FF8F8-BCD4-465D-ABED-993906C3165FQ48848031-20AC2424-F998-4925-A419-D6564CF91C85Q48887973-3BE7729C-567A-4FB5-B112-07D3175DC9A8Q51212386-7DFF189A-D8C8-4949-8813-0BDAC12B783AQ51245811-CAB0C75B-6D72-4EC3-9001-CA4EC4207CE8Q51271294-2029A05A-A67E-4233-BC6B-189A8639097CQ51777179-A8121D2B-8B83-4A5F-A986-0285440ED41CQ51996066-3DE74DBF-33C6-47C6-B634-8A31A4354C0B
P50
description
researcher ORCID ID = 0000-0002-5118-7050
@en
wetenschapper
@nl
name
David V Sheehan
@ast
David V Sheehan
@en
David V Sheehan
@es
David V Sheehan
@nl
type
label
David V Sheehan
@ast
David V Sheehan
@en
David V Sheehan
@es
David V Sheehan
@nl
prefLabel
David V Sheehan
@ast
David V Sheehan
@en
David V Sheehan
@es
David V Sheehan
@nl
P214
P106
P1153
21535932600
P2038
David_Sheehan2
P21
P214
P31
P496
0000-0002-5118-7050
P734
P7859
viaf-252418939